trending Market Intelligence /marketintelligence/en/news-insights/trending/3waymAdMUTDw7dWnsqSZwQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Revance raises $127.1M from stock offering

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Revance raises $127.1M from stock offering

Revance Therapeutics Inc. said it raised $127.1 million after underwriters of its previously announced offering fully exercised their overallotment option.

The Newark, Calif.-based biotechnology company sold 7,475,000 shares at $17 apiece, including the additional 975,000 shares as part of underwriters' overallotment option.

Cowen, Piper Jaffray & Co. and Stifel are joint lead book-running managers for the offering, with Guggenheim Securities serving as book-running manager and Needham & Co. as co-manager.

On Nov. 26, 2019, the company filed an application to the U.S. Food and Drug Administration seeking approval for Daxi, the company's competitor to Allergan PLC's botox.